COMMENTARY: N-terminal-pro-B-type natriuretic peptide testing reduced duration of ED visits in patients presenting with dyspnea

Murray, Heather
November 2007
ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p62
Academic Journal
The author reflects on the findings of a study, that investigated the use of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) testing to improve management, in dyspnea patients presenting to the emergency department (ED). He states that the study will help in reducing the crowd that is always seen in EDs. He mentions that reduction in cost of the patients tested with NT-proBNP was realized through a reduction in follow-up tests.


Related Articles

  • N-terminal-pro-B-type natriuretic peptide testing reduced duration of ED visits in patients presenting with dyspnea.  // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p62 

    The article offers information on a study that investigates the use of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) testing to improve management, in dyspnea patients presenting to the emergency department (ED). It describes the setting, patients' condition, and randomized controlled...

  • Interpretation and Use of Natriuretic Peptides in Non-Cnngestive Heart Fillure Settings. Shih-Hung Tsai; Yen-Yue Lin; Shi-Jye Chu; Ching-Wang Hsu; Shu-Meng Cheng // Yonsei Medical Journal;3/1/2010, Vol. 51 Issue 2, p151 

    Natriuretic peptides (NPs) have been found to be useful markers in differentiating acute dyspneic patients presenting to the emergency department (ED) and emerged as potent prognostic markers for patients with congestive heart failure (CHF). The best-established and widely used clinical...

  • B-Type Natriuretic Peptide Testing, Clinical Outcomes, and Health Services Use in Emergency Department Patients With Dyspnea. Schneider, Hans-Gerhard; Lam, Louisa; Lokuge, Amaali; Krum, Henry; Naughton, Matthew T.; De Villiers Smit, Pieter; Bystrzycki, Adam; Eccleston, David; Federman, Jacob; Flannery, Genevieve; Cameron, Peter // Annals of Internal Medicine;3/17/2009, Vol. 150 Issue 6, p365 

    Background: B-type natriuretic peptide (BNP) is used to diagnose heart failure, but the effects of using the test on all dyspneic patients is uncertain. Objective: To assess whether BNP testing alters clinical outcomes and health services use of acutely dyspneic patients. Design: Randomized,...

  • Brain Natriuretic Peptide Levels for Ruling Out Heart Failure. CULLAN, ALLISON; GROVER, MICHAEL; HITCHCOCK, KRISTIN // American Family Physician;6/1/2011, Vol. 83 Issue 11, p1333 

    The article provides information on excluding the possibility of heart failure based on the assessment of brain natriuretic peptide (BNP) levels. Researchers reviewed several clinical and laboratory cases involving adult patients diagnosed with dyspnea. Results showed that a 100 pg per mL level...

  • B-type natriuretic peptide or amino-terminal pro-B-type natriuretic peptide-guided treatment of heart failure: what is the next STEP? Troughton, Richard W.; Nicholls, M. Gary // European Journal of Heart Failure;Oct2011, Vol. 13 Issue 10, p1046 

    No abstract available.

  • Turnover Studies on Cardiac Natriuretic Peptides: Methodological, Pathophysiological and Therapeutical Considerations. Clerico, Aldo; Iervasi, Giorgio; Pilo, Alessandro // Current Drug Metabolism;Jul2000, Vol. 1 Issue 1, p85 

    Cardiac natriuretic peptide hormones (ANP and BNP) are synthesized and secreted by the heart, producing several biological effects, such as natriuresis, vasorelaxation, hypotension, and neuromodulation. Extensive studies conducted in both animals and humans have documented that cardiac...

  • Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Best, Patricia J.M.; Burnett Jr., John C.; Wilson, Stephanie H.; Holmes Jr., David R.; Lerman, Amir // Cardiovascular Research;Sep2002, Vol. 55 Issue 2, p375 

    Background: Dendroaspis natriuretic peptide (DNP) is the newest member of the natriuretic peptide family and is a circulating peptide in humans. The effects of DNP on the human vasculature are unknown. Since other natriuretic peptides are known to cause vasorelaxation, we determined the...

  • Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP Rosenkranz, Anke C.; Woods, Robyn L.; Dusting, Gregory J.; Ritchie, Rebecca H. // Cardiovascular Research;Feb2003, Vol. 57 Issue 2, p515 

    Atrial natriuretic peptide (ANP) prevents hypertrophy of neonatal cardiomyocytes. However, whether this effect is retained in the adult phenotype or if other members of the natriuretic peptide family exhibit similar antihypertrophic properties, has not been elucidated. Objective: Our...

  • Atrial natriuretic peptide concentrations in pre-eclampsia. Thomsen, Jorn Kvist; Storm, Tommy Lyager; Thamsborg, Gorm; de Nully, Michael; Dodker, Birgit; Skouby, Sven // British Medical Journal (Clinical Research Edition);6/13/1987, Vol. 294 Issue 6586, p1508 

    Examines the concentration of plasma immunoreactive atrial natriuretic peptide in pre-eclampsia. Expansion of plasma volume in normal pregnancy; Complications associated with pre-eclampsia during pregnancy; Investigation of low plasma atrial natriuretic peptide concentration in pre-eclampsia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics